Stable Supply of Essential Medicines and Dialysis Agents
First written in FY2016. 31 of 34 entries say "Restated". Latest entry: 2026-09-30.
No other company in this theme has enough history to compare yet.
- FY2026-H1RestatedAnnual report
「Because the company handles many essential medicines, including dialysis solutions for artificial kidneys and infusion products, and therefore has a significant responsibility to ensure stable supply, it routinely takes measures including immediately convening an emergency response meeting when an event is identified that could disrupt stable supply and working to resolve it as a priority, in preparation for sudden events such as natural disasters, including earthquakes, and novel coronavirus disease, which became a pandemic.」
The company positions the stable supply of essential medicines as a significant responsibility and continues measures including emergency response meetings for natural disasters, pandemics, and other events. - FY2024RestatedAnnual report
「As a company that manufactures and sells many essential medicines indispensable to medical care, including dialysis products, infusions, and injections, we regard their stable supply as a social mission. By operating mass-production plants in Okayama, Osaka, and Ibaraki and 12 distribution centers nationwide, we have established a comprehensive nationwide stable-supply system.」
The company regards the stable supply of essential medicines as a social mission and continues its supply system comprising 3 plants and 12 distribution centers nationwide. - FY2024-Q3RestatedAnnual report
「Because the company handles many essential medicines, including dialysis solutions for artificial kidneys and infusion products, and therefore has a significant responsibility to ensure stable supply, it routinely takes measures including immediately convening an emergency response meeting when an event is identified that could disrupt stable supply and working to resolve it as a priority, in preparation for sudden events such as natural disasters, including earthquakes, and novel coronavirus disease, which became a pandemic.」
The company positions the stable supply of essential medicines as a significant responsibility and continues measures through emergency response meetings. - FY2024-Q2RestatedAnnual report
「Because the company handles many essential medicines, including dialysis solutions for artificial kidneys and infusion products, and therefore has a significant responsibility to ensure stable supply, it routinely takes measures including immediately convening an emergency response meeting when an event is identified that could disrupt stable supply and working to resolve it as a priority, in preparation for sudden events such as natural disasters, including earthquakes, and novel coronavirus disease, which became a pandemic.」
The company positions the stable supply of essential medicines as a significant responsibility and continues measures through emergency response meetings. - FY2024-Q1RestatedAnnual report
「Because the company handles many essential medicines, including dialysis solutions for artificial kidneys and infusion products, and therefore has a significant responsibility to ensure stable supply, it routinely takes measures including immediately convening an emergency response meeting when an event is identified that could disrupt stable supply and working to resolve it as a priority, in preparation for sudden events such as natural disasters, including earthquakes, and novel coronavirus disease, which became a pandemic.」
The company positions the stable supply of essential medicines as a significant responsibility and continues measures including emergency response meetings for natural disasters, pandemics, and other events. - FY2023RestatedAnnual report
「As a company that manufactures and sells many essential medicines indispensable to medical care, including dialysis products, infusions, and injections, we regard their stable supply as a social mission. By operating mass-production plants in Okayama, Osaka, and Ibaraki and 12 distribution centers nationwide, we have established a comprehensive nationwide stable-supply system.」
The company positions the stable supply of essential medicines as a social mission and specifically describes its supply system comprising mass-production plants in Okayama, Osaka, and Ibaraki and 12 distribution centers nationwide. - FY2023-Q3RestatedAnnual report
「Because the company handles many essential medicines, including dialysis solutions for artificial kidneys and infusion products, and therefore has a significant responsibility to ensure stable supply, it routinely takes measures including immediately convening an emergency response meeting when an event is identified that could disrupt stable supply and working to resolve it as a priority, in preparation for sudden events such as natural disasters, including earthquakes, and novel coronavirus disease, which became a pandemic.」
The company positions the stable supply of essential medicines as a significant responsibility and continues measures including emergency response meetings for natural disasters and pandemics. - FY2023-Q2RestatedAnnual report
「Because the company handles many essential medicines, including dialysis solutions for artificial kidneys and infusion products, and therefore has a significant responsibility to ensure stable supply, it routinely takes measures including immediately convening an emergency response meeting when an event is identified that could disrupt stable supply and working to resolve it as a priority, in preparation for sudden events such as natural disasters, including earthquakes, and novel coronavirus disease, which became a pandemic.」
The company positions the stable supply of essential medicines as a significant responsibility and continues measures including emergency response meetings for natural disasters, pandemics, and other events. - FY2023-Q1RestatedAnnual report
「Because the company handles many essential medicines, including dialysis solutions for artificial kidneys and infusion products, and therefore has a significant responsibility to ensure stable supply, it routinely takes measures including immediately convening an emergency response meeting when an event is identified that could disrupt stable supply and working to resolve it as a priority, in preparation for sudden events such as natural disasters, including earthquakes, and novel coronavirus disease, which became a pandemic.」
The company positions the stable supply of essential medicines as a significant responsibility and continues measures including emergency response meetings for natural disasters, pandemics, and other events. - FY2022RestatedAnnual report
「The company handles many essential medicines, including dialysis solutions for artificial kidneys and infusion products, and therefore has a significant responsibility to ensure stable supply. To prepare for sudden events such as natural disasters, including earthquakes, and novel coronavirus disease, which became a pandemic, we have routinely taken measures including immediately convening an emergency response meeting when an event is identified that could disrupt stable supply and working to resolve it as a priority.」
The company positions the stable supply of essential medicines as a significant responsibility and continues measures including emergency response meetings. - FY2022-Q2RestatedAnnual report
「The company handles many essential medicines, including dialysis solutions for artificial kidneys and infusion products, and therefore has a significant responsibility to ensure stable supply. To prepare for sudden events such as natural disasters, including earthquakes, and novel coronavirus disease, we have routinely taken measures including immediately convening an emergency response meeting when an event is identified that could disrupt stable supply and working to resolve it as a priority. Manufacturing facilities are also distributed between eastern and western Japan, with product storage facilities established in various locations, and sufficient inventory secured to respond to unexpected demand.」
The company continues to position the stable supply of essential medicines as a significant responsibility and maintains measures including emergency response meetings, manufacturing sites distributed between eastern and western Japan, storage facilities in various locations, and inventory securing. - FY2021RestatedAnnual report
「The company handles many essential medicines, including dialysis solutions for artificial kidneys and infusion products, and therefore has a significant responsibility to ensure stable supply. To prepare for sudden events such as natural disasters, including earthquakes, and novel coronavirus disease, which became a pandemic, we have routinely taken measures including immediately convening an emergency response meeting when an event is identified that could disrupt stable supply and working to resolve it as a priority.」
The company positions the stable supply of essential medicines as a significant responsibility and continues measures including emergency response meetings. - FY2021-Q3RestatedAnnual report
「The company handles many essential medicines, including dialysis solutions for artificial kidneys and infusion products, and therefore has a significant responsibility to ensure stable supply. To prepare for sudden events such as natural disasters, including earthquakes, and novel coronavirus disease, we have routinely taken measures including immediately convening an emergency response meeting when an event is identified that could disrupt stable supply and working to resolve it as a priority.」
The company positions the stable supply of essential medicines as a significant responsibility and continues measures including emergency response meetings. - FY2021-Q2RestatedAnnual report
「The company handles many essential medicines, including dialysis solutions for artificial kidneys and infusion products, and therefore has a significant responsibility to ensure stable supply. To prepare for sudden events such as natural disasters, including earthquakes, and novel coronavirus disease, we have routinely taken measures including immediately convening an emergency response meeting when an event is identified that could disrupt stable supply and working to resolve it as a priority.」
The company positions the stable supply of essential medicines as a significant responsibility and continues measures including emergency response meetings. - FY2021-Q1RestatedAnnual report
「The company handles many essential medicines, including dialysis solutions for artificial kidneys and infusion products, and therefore has a significant responsibility to ensure stable supply. To prepare for sudden events such as natural disasters, including earthquakes, and novel coronavirus disease, we have routinely taken measures including immediately convening an emergency response meeting when an event is identified that could disrupt stable supply and working to resolve it as a priority.」
The company reaffirmed its significant responsibility to ensure a stable supply of essential medicines and describes measures including emergency response meetings, manufacturing sites dispersed between eastern and western Japan, product storage facilities in various locations, and inventory securing. - FY2020RestatedAnnual report
「To prepare for sudden events such as natural disasters, including earthquakes, and the novel coronavirus disease, which became a pandemic, we have routinely taken measures including immediately convening an emergency response meeting when an event is identified that could disrupt stable supply and working to resolve it as a priority.」
The company continues its policy of ensuring a stable supply of essential medicines and specifically describes measures such as emergency response meetings to prepare for natural disasters and pandemics. - FY2020-Q3RestatedAnnual report
「As the leading manufacturer of dialysis products, we regard the stable supply of dialysis products, which are indispensable to dialysis patients, as our top priority. We will develop new demand markets and promote sales expansion for products including dialysis solutions, replacement fluids for hemodialysis, physiological saline, anticoagulants for dialysis-related products, adsorption-type blood purification devices, and dialyzers.」
The company continues to pursue a policy of making the stable supply of dialysis products its top priority and developing new demand markets and expanding sales of related products. - FY2020-Q2RestatedAnnual report
「As the leading manufacturer of dialysis products, we regard the stable supply of dialysis products, which are indispensable to dialysis patients, as our top priority. We will develop new demand markets and promote sales expansion for products including dialysis solutions, replacement fluids for hemodialysis, physiological saline, anticoagulants for dialysis-related products, adsorption-type blood purification devices, and dialyzers.」
The company continues to pursue a policy of making the stable supply of dialysis products its top priority and developing new demand markets and expanding sales of dialysis-related products. - FY2020-Q1RestatedAnnual report
「As the leading manufacturer of dialysis products, we regard the stable supply of dialysis products, which are indispensable to dialysis patients, as our top priority. We will develop new demand markets and promote sales expansion for products including dialysis solutions, replacement fluids for hemodialysis, physiological saline, anticoagulants for dialysis-related products, adsorption-type blood purification devices, and dialyzers.」
The company continues to pursue a policy of making the stable supply of dialysis products its top priority and developing new demand markets and expanding sales of dialysis-related products. - FY2019RestatedAnnual report
「As an industry involved in life and health, we will fulfill our responsibility by developing and ensuring a stable supply of pharmaceuticals that meet growing and diversifying medical needs, against a backdrop of an aging society, advances in medical technology, and the public's growing focus on health and welfare」
The company continues to pursue the development and stable supply of pharmaceuticals that meet medical needs as its basic policy. - FY2019-Q3RestatedAnnual report
「As the leading manufacturer of dialysis products, we regard the stable supply of dialysis products, which are indispensable to dialysis patients, as our top priority. We will develop new demand markets and promote sales expansion for products including dialysis solutions, replacement fluids for hemodialysis, physiological saline, anticoagulants for dialysis-related products, adsorption-type blood purification devices, and dialyzers.」
The company continues to make the stable supply of dialysis products its top priority while developing new demand markets and expanding sales of related products. - FY2019-Q2RestatedAnnual report
「As the leading manufacturer of dialysis products, we regard the stable supply of dialysis products, which are indispensable to dialysis patients, as our top priority. We will develop new demand markets and promote sales expansion for products including dialysis solutions, replacement fluids for hemodialysis, physiological saline, anticoagulants for dialysis-related products, adsorption-type blood purification devices, and dialyzers.」
The company continues to pursue a policy of making the stable supply of dialysis products its top priority. - FY2019-Q1RestatedAnnual report
「As the leading manufacturer of dialysis products, we regard the stable supply of dialysis products, which are indispensable to dialysis patients, as our top priority. We will develop new demand markets and promote sales expansion for products including dialysis solutions, replacement fluids for hemodialysis, physiological saline, anticoagulants for dialysis-related products, adsorption-type blood purification devices, and dialyzers.」
The company continues to pursue a policy of making the stable supply of dialysis products its top priority and developing new demand markets and expanding sales of related products. - FY2018RestatedAnnual report
「In addition to working to ensure a stable supply of essential medicines such as infusion products, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, to secure earnings, while also focusing on promoting sales of generic drugs.」
The company continues to identify the stable supply of essential medicines, particularly dialysis products, as a priority. - FY2018-Q3RestatedAnnual report
「As the leading manufacturer of dialysis products, we regard the stable supply of dialysis products, which are indispensable to dialysis patients, as our top priority. We will develop new demand markets and promote sales expansion for products including dialysis solutions, replacement fluids for hemodialysis, physiological saline, anticoagulants for dialysis-related products, adsorption-type blood purification devices, and dialyzers.」
The company continues to pursue a policy of making the stable supply of dialysis products its top priority. - FY2018-Q1RestatedAnnual report
「As the leading manufacturer of dialysis products, we regard the stable supply of dialysis products, which are indispensable to dialysis patients, as our top priority. We will develop new demand markets and promote sales expansion for products including dialysis solutions, replacement fluids for hemodialysis, physiological saline, anticoagulants for dialysis-related products, adsorption-type blood purification devices, and dialyzers.」
The company continues to pursue a policy of making the stable supply of dialysis products its top priority. - FY2017RestatedAnnual report
「As an industry involved in life and health, we will fulfill our responsibility by developing and ensuring a stable supply of pharmaceuticals that meet growing and diversifying medical needs, against a backdrop of an aging society, advances in medical technology, and the public's growing focus on health and welfare」
The company continues to pursue the development and stable supply of pharmaceuticals as its basic policy. - FY2017-Q3RestatedAnnual report
「Under these circumstances, in addition to working to ensure a stable supply of essential medicines such as infusion products, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, while focusing on promoting sales of generic drugs such as Levocarnitine Chloride Tablets, a treatment for carnitine deficiency, and Naftopidil OD Tablets, a treatment for urinary disorders.」
The company continues to pursue its policy of ensuring a stable supply of essential medicines and products related to hemodialysis. - FY2017-Q2RestatedAnnual report
「Under these circumstances, in addition to working to ensure a stable supply of essential medicines such as infusion products, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, while focusing on promoting sales of generic drugs such as Levocarnitine Chloride Tablets, a treatment for carnitine deficiency, and Naftopidil OD Tablets, a treatment for urinary disorders.」
The company continues to pursue its policy of ensuring a stable supply of essential medicines and products related to hemodialysis. - FY2017-Q1RestatedAnnual report
「Under these circumstances, in addition to working to ensure a stable supply of essential medicines such as infusion products, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, to secure earnings, while focusing on promoting sales of generic drugs such as Naftopidil OD Tablets, a treatment for urinary disorders, and Levocarnitine Chloride Tablets, a treatment for carnitine deficiency.」
The company continues to pursue its policy of ensuring a stable supply of essential medicines and products related to hemodialysis. - FY2016First statedAnnual report
「In addition to working to ensure a stable supply of essential medicines such as infusion products, we will seek to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, to secure earnings.」
Stable supply of essential medicines, particularly dialysis products, is identified as a key priority. The company has also indicated that it will strengthen its supply system, including for disasters.